Introduction: The aim of this study was to compare the accuracy of 5 blood glucose monitoring systems (BGMSs; CONTOUR Ò PLUS [CP], Accu-Chek Ò Active [ACA], Accu-Chek Ò Performa [ACP], FreeStyle Freedom TM [FF], OneTouch Ò SelectSimple TM [OTSS]). Methods: Study staff tested fingerstick samples from 106 subjects aged C18 years using the 5 BGMSs. Some samples were modified to Funding: Bayer HealthCare LLC, Diabetes Care. Trial registration number: ClinicalTrials.gov Identifier NCT01714232.
Results: CONTOUR Ò PLUS had a statistically significantly lower MARD than all BGMSs across the overall tested range (27-460 mg/dL [1.5-25 .5 mmol/L]) and in the high glucose range. In the low glucose range, CP had a lower MARD than all BGMSs, which was statistically significant except for ACP. For unmodified samples across the overall tested range, CP had a lower MARD than all BGMSs and was statistically significantly lower except for ACA.
Conclusions: CONTOUR Ò PLUS had the lowest mean difference from the reference values (by MARD) when compared with other BGMSs across multiple glucose ranges with modified and unmodified samples.
INTRODUCTION
Self-monitoring of blood glucose (SMBG) is an important component of a comprehensive diabetes care plan and can help people with diabetes achieve glycemic control [1, 2] . The accuracy of SMBG results is an important consideration because these results are often used to make diabetes management decisions [3] [4] [5] [6] [7] . SMBG helps detect hypoglycemia and hyperglycemia and helps reduce glycemic variability, which has been shown to have an impact on diabetes complications [8] [9] [10] .
Because SMBG results can be used to guide the self-care practices of people with diabetes, it is important for the blood glucose monitoring system (BGMS) to provide accurate results [3] [4] [5] . Performance evaluations of BGMSs for regulatory purposes may include the use of criteria of the International Organization for Standardization (ISO 15197:2013 [11] ).
Furthermore, Parkes-Consensus Error Grid analysis [12] may be used to evaluate the clinical impact of the error in measurement of blood glucose.
ISO guidelines were developed based on the need to establish requirements that result in acceptable performance of BGMSs and to specify procedures for demonstrating conformance. According to ISO guidelines, accuracy is based on the absolute difference of BGMS results from the reference result in lower glucose ranges, and the absolute relative (percent) difference of BGMS results from the reference result in higher glucose ranges; ISO requirements state that C95% of results shall fall within specified margins of error [11, 13] . Specifically, the ISO 15197:2003 standard required that C95% of results were within ±15 mg/dL (±0.8 mmol/L) or ±20% of the reference result for samples with glucose concentrations \75 mg/dL (\4.2 mmol/L) and C75 mg/dL (C4.2 mmol/L), respectively [13] . Tighter accuracy criteria were adopted with the ISO 15197:2013 standard, which requires that C95% of results fall within ±15 mg/dL (±0.8 mmol/L) or ±15% of the reference result for samples with glucose concentrations \100 mg/dL (\5.6 mmol/L) and C100 mg/dL (C5.6 mmol/L), respectively [11] . However, even though commercially available BGMSs have met the accuracy criteria required to be permitted to enter a specific regional market, differences exist in overall performance [14] [15] [16] [17] [18] For testing the modified blood samples, a fresh drop of blood was removed from the tube just prior to each meter test (after being placed on Parafilm or similar) and was tested promptly to avoid evaporation. All blood samples were tested on the 5 BGMSs using a test order rotation throughout the study. A single test strip lot per meter system was used for testing all samples.
After the meter tests, the remaining blood in the tube was immediately centrifuged for testing on a Yellow Springs Instruments (YSI) laboratory glucose analyzer (YSI Life Sciences, Inc., Yellow Springs, OH, USA). The time from the first meter test to centrifugation was not to exceed 15 min (mean ± SD interval 2.3 ± 1.2 min; range 1-7 min). The accuracy and precision of the 2 YSI analyzers were monitored throughout the study using 6 serum traceability control levels that spanned the range from 23.5 mg/dL (1.3 mmol/L) to 585 mg/dL (32.5 mmol/L). The target glucose levels for the controls had been previously determined using a reference method traceable to the National Institute of Standards and Technology Standard Reference Material 965a Glucose in Frozen Human Serum (aqueous New England Reagents Laboratory Glucose Standards) [21] . represented by dashed lines. The points were differentiated by unique symbols, denoting whether the blood samples were modified or unmodified. Measured glucose values most similar to YSI reference values were indicated by points nearest the horizontal line (y = 0). To assess clinical accuracy, Parkes-Consensus Error Grid analysis [12] was performed for each BGMS. Adverse events (AEs) were monitored throughout the study. 
Assessments and Analyses
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RESULTS
Subjects
A total of 106 subjects aged 18-84 years were enrolled and completed the study. Most subjects (n = 90) had type 2 diabetes, 8 subjects had type 1 diabetes, 2 subjects had diabetes of unknown type, and 6 subjects did not have diabetes (Table 1) .
Blood Samples
For each BGMS, 105 unmodified blood samples and 209 modified capillary blood samples were analyzed. Unmodified and modified blood samples from 1 subject were not included in the accuracy analyses because hematocrit was [55%, which is outside the hematocrit range that is specified in the labeling for 2 of the 4 BGMSs tested (ACA and OTSS). The third sample from another subject was glycolyzed, resulting in a YSI value of 12.3 mg/dL (0.68 mmol/L). This sample was, therefore, not evaluable because its YSI value was below the minimum glucose limit of 20 mg/dL (1. statistically significantly lower than all systems except for the ACA BGMS (Table 2) .
Modified Bland-Altman plots for each BGMS are shown in Fig. 1a-e 
DISCUSSION
Using an accurate BGMS may help people with diabetes to use their blood glucose values from SMBG to make better informed decisions about their diabetes management [3] [4] [5] [6] [7] . MARD analysis is useful for comparing the accuracy of multiple meters in a single study [19] . In this study, the CP BGMS had a statistically significantly lower MARD in the overall glucose range (27- [12] . There were no results within Zones C, D, or E; results in these zones would indicate altered clinical action with increasingly severe effects on clinical outcome.
In addition to the choice of meters for evaluation, comparative analyses of meter accuracy may involve differences in study design. Such differences should be considered when assessing the results of comparative analyses. For example, meters may be compared based on their ability to fulfill ISO accuracy criteria or using MARD analysis. Being continuously valued (i.e., a decimal number), MARD facilitates the use of powerful methods for comparing multiple meters simultaneously (e.g., ANOVA). Furthermore, as the clinical risk associated with meter inaccuracy varies depending on blood glucose concentration, evaluation of meter accuracy in the low, middle, and high glucose ranges in addition to the overall glucose range provides a more complete assessment of accuracy than does evaluation in the overall glucose range only.
As patients with diabetes often have comorbidities such as hyperlipidemia or chronic kidney disease and may also be taking multiple medications [22, 23] , health care providers and people with diabetes should also be aware of agents that could interfere with the accuracy of blood glucose results (Table 4 ). For example, maltose can interfere with some SMBG systems, leading to anomalously high glucose measurements that could mask hypoglycemia or give an inaccurate indication of hyperglycemia [3] . Maltose can be found in certain immunoglobulin products, and it is a metabolic by-product of the icodextrin that is used in peritoneal dialysis.
Chronic diseases, including diabetes, present serious health concerns, and their prevalence is increasing in low-, middle-, and high-income countries [24] . Relatively simple and costeffective steps can be taken to prevent or significantly delay the onset of diabetes and its complications [25] . For people with diabetes, treatment and clinical monitoring to achieve glycemic and metabolic control are core components of effective diabetes care [25] . However, contributing factors to suboptimal glycemic control include underutilization of blood glucose data and the use of glycated hemoglobin as the sole measure of glycemic control [26] . SMBG is an integral component of diabetes management and helps people with [1, 2] , especially when they are educated about how to act on their results [5, 9, 27, 28] 
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